"The third quarter of the previous fiscal includes revenues of Rs 99.3 crore for Fluoxetine 40 mg capsules and Rs 10.8 crore R&D licence fee," she said adding "excluding the same, the net sales have registered a growth of 31 per cent as per the Indian GAAP. During the quarter under review, the company registered a sales income of Rs 36.31 crore from Fluoxetine 40 mg. While the income from R&D is nil for the quarter.
During the quarter under review, the company has posted a net sale of Rs 396.43 crore (Rs 411.91 crore). While the API and formulation business has reported a growth of Rs 168.51 crore and Rs 171.95 crore respectively during the Q3 2002-03, as against Rs 152.13 crore and Rs 155.12 crore respectively for the same period in the previous year. However, the generic business has reported a fall from Rs 115.38 crore in the Q3 of 2001-02 to Rs 78.55 crore for the quarter under review.
Under APIs, the company has filed five DMFs during the quarter taking the total to 36. Further it has filed three ANDAs with Para IV certification taking the total ANDA filings to 30. While the total filings pending approval with the USFDA is at 19, the company stated. In the Russian market the branded formulations such as Omez, Enam, Cipro and Nise have grown by 31 per cent, as against 21 per cent growth in Indian market. The company board has approved a further investment of Rs 50 crore in the equity of Aurigene Discovery Technologies Ltd, a wholly-owned subsidiary promoted to enter the research services market.